Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BY-NC 4.0Cancer Biology & Therapy

The p16 isoform of CDKN2A inhibits ferroptosis to promote the progression of papillary thyroid carcinoma by influencing the p53/SLC7A11/GPX4 pathway

6 affiliations
  1. 1Shandong Provincial Key Laboratory of Neuroimmune Interaction and Regulation, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China
  2. 2Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China
  3. 3Shandong Provincial Clinical Research Center for Otorhinolaryngologic Diseases, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China
  4. 4Yantai Key Laboratory of Otorhinolaryngologic Diseases, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China
  5. 5Department of Neurology, Yantai Yuhuangding Hospital, Qingdao University, Yantai, China
  6. 6Yantai Municipal Key Medical and Health Laboratory of Yantai Yuhuangding Hospital (Interdisciplinary Brain Science and Geriatric Health Laboratory), Qingdao University, Yantai, China

Abstract

Background: Although papillary thyroid carcinoma (PTC) has a relatively good prognosis, it is also prone to recurrence and metastasis. Cyclin-dependent kinase inhibitor 2 A (CDKN2A) can affect tumor progression by regulating ferroptosis, but its role in PTC remains unclear.

Materials and methods: The expression of CDKN2A, p14, p16, GPX4, and TFRC in PTC was assessed by qPCR, western blotting, and immunohistochemistry, and their clinical correlations were analyzed. In TPC-1 and BCPAP cells, CDKN2A/p14/p16 expression was modulated, followed by evaluation of ferroptosis-related changes using GPX4, TFRC, Fe2⁺, ROS, GSH, C11-BODIPY lipid peroxidation, and transmission electron microscopy. Cell proliferation and migration were assessed by CCK-8, colony formation, wound-healing, and Transwell assays. The p53/SLC7A11/GPX4 pathway was examined, and rescue experiments were conducted using p53 agonist and inhibitor. In vivo tumorigenicity was evaluated using a nude mouse xenograft model.

Results: CDKN2A was upregulated in PTC and associated with advanced clinicopathological features and lipid metabolism, but was not an independent prognostic factor. Silencing CDKN2A (p14, p16) induced ferroptosis, inhibiting tumor progression; in contrast, overexpression of p14 and p16 inhibited ferroptosis and promoted malignant phenotypes, with p16 playing a predominant role. Moreover, overexpression of p16 could partially resist the induction of ferroptosis by RSL3. Mechanistically, p53 agonist/inhibitor rescue experiments suggested p16 affected p53/SLC7A11/GPX4 pathway. In vivo, p16 overexpression increased tumor growth by inhibiting ferroptosis.

Conclusion: CDKN2A promotes PTC progression by suppressing ferroptosis via indirect regulation of p53/SLC7A11/GPX4 pathway, primarily through the p16 isoform. Targeted inhibition of p16 isoform is a potential therapeutic strategy for PTC.

Related

  1. Statement of Retraction: Long noncoding RNA MALAT1 knockdown inhibits progression of anaplastic thyroid carcinoma by regulating miR-200a-3p/FOXA1.
    Cancer biology & therapyPeer-reviewedCC BYFull textOncologyEurope PMC
  2. ECM stiffness inhibits ferroptosis to promote HCC progression via the FOXA1-CDON-HMGB1/p53 pathway.
    Qianben Song, Xilin Ye, Xin Mao +4
    International journal of biological sciencesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. CDCA5 promotes hepatocellular carcinoma progression by suppressing ferroptosis through PP2Ac/p53/STEAP3 signaling
    Di Wu, Haonan Zhou, Shiqi Liu +5
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicineCrossref
  4. Semaglutide, Other GLP-1 Receptor Agonists, and Papillary Thyroid Carcinoma: A Narrative Review of Risk, Progression, and Mechanisms
    Luiza Barseghyan, Iqbal Munir, Steven Chrysafide +2
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0Full textEndocrinology & metabolismCrossrefEurope PMC
  5. Hybrid grading systems improve progression risk stratification in non‐invasive papillary urothelial carcinoma and support a histomorphological continuum of disease progression
    Jane K Nguyen, Marcello P Toscano, Jianbo Li +14
    HistopathologyPeer-reviewedCC BY 4.0Full text1 citedSurgery & anaesthesiaPMC
BibTeX
@article{wang2026isoform,
  title = {{The p16 isoform of CDKN2A inhibits ferroptosis to promote the progression of papillary thyroid carcinoma by influencing the p53/SLC7A11/GPX4 pathway}},
  author = {Yao Wang and Ya-Kui Mou and Ting Yang and Han-Rui Wang and Xiao-Yu Song and Wan-Chen Liu and Hui Shen and Chao Ren and Xi-Cheng Song},
  journal = {Cancer Biology \& Therapy},
  year = {2026},
  month = nov,
  doi = {10.1080/15384047.2026.2760033},
  url = {https://doi.org/10.1080/15384047.2026.2760033},
  note = {CC BY-NC 4.0},
}
RIS
TY  - JOUR
TI  - The p16 isoform of CDKN2A inhibits ferroptosis to promote the progression of papillary thyroid carcinoma by influencing the p53/SLC7A11/GPX4 pathway
AU  - Yao Wang
AU  - Ya-Kui Mou
AU  - Ting Yang
AU  - Han-Rui Wang
AU  - Xiao-Yu Song
AU  - Wan-Chen Liu
AU  - Hui Shen
AU  - Chao Ren
AU  - Xi-Cheng Song
PY  - 2026
DA  - 2026/11/11
JO  - Cancer Biology & Therapy
DO  - 10.1080/15384047.2026.2760033
UR  - https://doi.org/10.1080/15384047.2026.2760033
AB  - Background: Although papillary thyroid carcinoma (PTC) has a relatively good prognosis, it is also prone to recurrence and metastasis. Cyclin-dependent kinase inhibitor 2 A (CDKN2A) can affect tumor progression by regulating ferroptosis, but its role in PTC remains unclear.  Materials and methods: The expression of CDKN2A, p14, p16, GPX4, and TFRC in PTC was assessed by qPCR, western blotting, and immunohistochemistry, and their clinical correlations were analyzed. In TPC-1 and BCPAP cells, CDKN2A/p14/p16 expression was modulated, followed by evaluation of ferroptosis-related changes using GPX4, TFRC, Fe2⁺, ROS, GSH, C11-BODIPY lipid peroxidation, and transmission electron microscopy. Cell proliferation and migration were assessed by CCK-8, colony formation, wound-healing, and Transwell assays. The p53/SLC7A11/GPX4 pathway was examined, and rescue experiments were conducted using p53 agonist and inhibitor. In vivo tumorigenicity was evaluated using a nude mouse xenograft model.  Results: CDKN2A was upregulated in PTC and associated with advanced clinicopathological features and lipid metabolism, but was not an independent prognostic factor. Silencing CDKN2A (p14, p16) induced ferroptosis, inhibiting tumor progression; in contrast, overexpression of p14 and p16 inhibited ferroptosis and promoted malignant phenotypes, with p16 playing a predominant role. Moreover, overexpression of p16 could partially resist the induction of ferroptosis by RSL3. Mechanistically, p53 agonist/inhibitor rescue experiments suggested p16 affected p53/SLC7A11/GPX4 pathway. In vivo, p16 overexpression increased tumor growth by inhibiting ferroptosis.  Conclusion: CDKN2A promotes PTC progression by suppressing ferroptosis via indirect regulation of p53/SLC7A11/GPX4 pathway, primarily through the p16 isoform. Targeted inhibition of p16 isoform is a potential therapeutic strategy for PTC.
SN  - 1538-4047
SN  - 1555-8576
ER  -